Mean cost per number needed to treat with tocilizumab plus methotrexate versus abatacept plus methotrexate in the treatment of rheumatoid arthritis in patients previously treated with methotrexate

INTRODUCTION: Biological disease-modifying antirheumatic drugs are particularly recommended for use in patients who are poor responders, are intolerant to conventional disease-modifying antirheumatic drugs (cDMARDs), or in whom continued treatment with cDMARDs is deemed inappropriate. We estimated t...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clinicoecon Outcomes Res
Autors principals: Benucci, Maurizio, Ravasio, Roberto, Damiani, Arianna
Format: Artigo
Idioma:Inglês
Publicat: Dove Medical Press 2017
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5525457/
https://ncbi.nlm.nih.gov/pubmed/28765712
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S141610
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars